Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

Modern Rheumatology
Naoto YokogawaFukumi Furukawa

Abstract

Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren's syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p < 0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p < 0.0001). CLASI is a reliable indicator to evaluate th...Continue Reading

References

Dec 24, 2008·Annals of the Rheumatic Diseases·G Ruiz-IrastorzaM A Khamashta
Jan 24, 2009·Autoimmunity Reviews·Tetsuya Tsuchida
Mar 18, 2009·Archives of Dermatology·Alexander KreuterThilo Gambichler
Aug 4, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Falk R Ochsendorf
Aug 10, 2010·Lupus·J Albrecht, V P Werth
Feb 5, 2011·Ophthalmology·Michael F MarmorUNKNOWN American Academy of Ophthalmology
Dec 16, 2011·The Journal of Dermatology·Takaharu IkedaFukumi Furukawa
Jun 5, 2012·The Journal of Rheumatology·Mitsumasa KishimotoMasato Okada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.